

INDUSTRY-ACADEMIC-CLINICAL FORUM

FUTURE TRENDS IN NANOMEDICINE FOR DIAGNOSTICS AND THERAPY IN ONCOLOGY

Parc Científic de Barcelona / Barcelona Science Park
25th of October of 2012

TABLE OF CONTENTS

	<u>Page</u>
Agenda	2
Practical Aspects	3
Order of Presentations	4 – 5
Plan of Rooms and Tables for Meetings (Partnering)	6

WITH THE COLLABORATION OF



NANOMEDICINE FOR DIAGNOSTICS AND THERAPY IN ONCOLOGY

AGENDA

Date: 25th of October of 2012

Place: Barcelona Science Park - Towers R+D+I
Auditorium in Hall Tower D (ground floor)
4, Baldiri Reixach street
08029 Barcelona

8.30 - 8.55 **Registration**

8.55 - 9.05 **Welcome**

Dr. Jesús Purroy, Scientific Director, PCB
Mr. Carlos Lurigados, Project Director, Biocat

9.05 - 9.10 **Practical issues for the development of the forum**

Dr. Fernando Santos, Technology Transfer Manager, CIBER-BBN

9.10 - 11.10 **Research Groups flash presentations** (5 minutes each)

Please, see order of presentations in page 4

11.10 - 11.30 **Coffee break**

11.30 - 13.25 **Clinical Groups and Companies flash presentations** (5 minutes each).

Please, see order of presentations in page 5

13.25 – 13.30 **Closing remarks**

Dr. Pablo Laguna, Scientific Director, CIBER-BBN

13.30 – 14.30 **Lunch**

14.30 - 20.00 **One-to-one meetings** (15 minutes each)

WITH THE COLLABORATION OF

PRACTICAL ASPECTS

1) Flash Presentations:

- a. English will be used for presentations.
- b. We kindly request to comply to 5 minutes presentations.
- c. No time for questions will exist between the different presentations. Further information will be provided at one-to-one meetings (partnering).

2) Partnering Meetings:

- a. Use the partnering tool to request and accept meetings.
Register / Log-in: http://www.plataformatecnologiasanitaria.es/partnering_evento.php?l=7
- b. Partnering meetings will have duration of 15 minutes. Punctuality and adjustment to the meeting schedule will be requested.
- c. The time should be sufficient to identify important mutual interests and to organize future meetings. The partners are encouraged to set-up another date for deeper discussion, if necessary.

3) Wi-Fi:

At Barcelona Science Park, on 25th of October.

User: ciber-guest

Password: UARS7CXv

4) Questions to:

fsantos@ciber-bbn.es

Fernando Santos

Technology Transfer Manager, CIBER-BBN

NANOMEDICINE FOR DIAGNOSTICS AND THERAPY IN ONCOLOGY

9.10 – 11.10 Research Groups Flash Presentations (5 min. each)

- | | | |
|----|---|-------------------------|
| 1 | Anticancer Therapy Group ,
University of Barcelona, Barcelona, Spain | Dr. Carles J. Ciudad |
| 2 | Centre of Research in Toxicology (Ceretox)
Barcelona, Spain | Dr. Miquel Borrás |
| 3 | Small System and Biomolecule Physics Group (BIOSMALL-UB)
University of Barcelona, CIBER-BBN, Barcelona, Spain | Dr. Félix Ritort |
| 4 | Nanobiosensors and Bioanalytical Applications (CIN2-CSIC)
Spanish National Research Council (CSIC), CIBER-BBN, Barcelona, Spain | Dr. Laura Lechuga |
| 5 | Drug Delivery and Targeting Group (GDLF-HUVH)
University Hospital Vall d'Hebron, CIBER-BBN, Barcelona, Spain | Dr. Ibane Abásolo |
| 6 | Applied Microbiology Research Group (IBB-UAB)
Biotechnology and Biomedicine Institute (UAB) CIBER-BBN, Barcelona, Spain | Dr. Esther Vázquez |
| 7 | Oncogenesis and Antitumor Group (GOA-HSCSP)
Research Inst., Hospital de la Santa Cruz y San Pablo, CIBER-BBN, Barcelona, Spain | Dr. Ramón Mangues |
| 8 | Nucleic Acid Chemistry Group (GQNA-CSIC)
Institute for Advanced Chemistry of Catalonia (CSIC), CIBER-BBN, Barcelona, Spain | Dr. Ramón Eritja |
| 9 | Nanoparticle and Peptide Chemical Group (IRB)
Biomedicine Research Institute, CIBER-BBN, Barcelona, Spain | Dr. Miriam Royo |
| 10 | Nanomedicine Group (NANOMED-IBEC)
Bioengineering Institute of Catalonia (IBEC), CIBER-BBN, Barcelona, Spain | Dr. Josep Samitier |
| 11 | Molecular Nanoscience and Organic Materials Group (NANOMOL-CSIC)
Materials Science Institute of Barcelona (CSIC), CIBER-BBN, Barcelona, Spain | Dr. Santiago Sala |
| 12 | Nanobiotechnology for Diagnostics (NB4D-IQAC)
Institute for Advanced Chemistry of Catalonia (CSIC), CIBER-BBN, Barcelona, Spain | Dr. Pilar Marco |
| 13 | Structural Mechanics and Material Modeling Group (GEMM-I3A)
Engineering Research Inst. of Aragón (U. of Zaragoza), CIBER-BBN, Zaragoza, Spain | Dr. Luis J. Fernández |
| 14 | Multifunctional Molecular Magnetic Materials Group (M4-CSIC)
Materials Science Institute of Aragón (CSIC), CIBER-BBN, Zaragoza, Spain | Dr. Fernando Palacio |
| 15 | Bioengineering and Telemedicine Group (GBT-UPM)
Universidad Politécnica de Madrid, CIBER-BBN, Madrid, Spain | Dr. José Javier Serrano |
| 16 | Molecular Immunobiology Laboratory (LIBM-HGUGM)
University Hospital Gregorio Marañón, CIBER-BBN, Madrid, Spain | Dr. M. Ángeles Muñoz |
| 17 | Dendrimer Group for Biomedical Applications (GDAB-UAH)
University of Alcalá de Henares, CIBER-BBN, Alcalá de Henares (Madrid) Spain | Dr. Rafael Gómez |
| 18 | Applied Molecular Chemistry Group (IQMA-UPV)
Applied Mol. Chem. Inst. (U. Politécnica de Valencia), CIBER-BBN, Valencia, Spain | Dr. Ramón Martínez |
| 19 | Group for Advanced Materials and Nanobiotechnology (BIOFORGE-UVA)
University of Valladolid, CIBER-BBN, Valladolid, Spain | Dr. Alessandra Girotti |
| 20 | CIBER-BBN Research Services
Zaragoza, Spain | Dr. Jesús M. Izco |
| 21 | Neuroprosthesis and Neuroengineering Research Group (NN-UMH)
University Miguel Hernández, CIBER-BBN, Elche (Alicante), Spain | Dr. Eduardo Fernández |

WITH THE COLLABORATION OF

NANOMEDICINE FOR DIAGNOSTICS AND THERAPY IN ONCOLOGY

11.30 – 13.25 Clinical Groups and Companies Flash Presentations (5 min. each)


- | | | |
|----|--|---------------------------|
| 1 | Laboratory Research Cancer Group / Oncology Pathology Research Group
IRB Lleida, Hospital Arnau de Vilanova, Lleida, Spain | Dr. Xavier Matias-Guiu |
| 2 | Diagnosis and therapy in oncology
IDIBAPS (Hospital Clinic) Barcelona, Spain | Dr. David Fuster |
| 3 | Biological Markers in Oncology
IDIBAPS (Hospital Clinic) Barcelona, Spain | Dr. Rafael Molina |
| 4 | Colorectal Cancer Group
IDIBELL (Hospital de Bellvitge), Barcelona, Spain | Dr. Victor Moreno |
| 5 | Breast Cancer Group
IDIBELL (Hospital de Bellvitge), Barcelona, Spain | Dr. Ander Urruticoechea |
| 6 | Sarcoma Research Group
IDIBELL (Hospital de Bellvitge), Barcelona, Spain | Dr. Óscar Martínez-Tirado |
| 7 | Research Unit in Biomedicine and Translational and Pediatrics Oncology
Research Institute, Vall d'Hebron University Hospital, Barcelona, Spain | Dr. Jaume Reventós |
| 8 | Transbiomed
Barcelona, Spain | Dr. Marcelo Viegas |
| 9 | VCN Biosciences
L'Hospitalet de Llobregat (Barcelona) Spain | Dr. Manel Cascalló |
| 10 | Advanced Marker Discovery (AMADIX)
Madrid, Spain | Dr. Ana Martín |
| 11 | TCD Pharma
Valladolid, Spain | Dr. Nicholas Ocleston |
| 12 | Apointech
Villamayor (Salamanca), Spain | Dr. Emmanuel Fajardo |
| 13 | Argon Pharma
Barcelona, Spain | Dr. Óscar Peña |
| 14 | BCN Peptides.
Sant Quintí de Mediona (Barcelona) Spain | Dr. Lluís Riera |
| 15 | Endor Nanotechnologies
Barcelona, Spain | Dr. Luciano Sobrevals |
| 16 | Ferrer Group
Barcelona, Spain | Dr. Andrés G. Fernández |
| 17 | Gendiag
Barcelona, Spain | Dr. Eduardo Salas |
| 18 | Lykera Biomed
Barcelona, Spain | Dr. Francesc Mitjans |
| 19 | NTE-Sener
Cerdanyola del Vallès (Barcelona) Spain | Dr. Josep M. Escuer |
| 20 | Vivia Biotech
Tres Cantos (Madrid) Spain | Dr. Resu Alloza |

WITH THE COLLABORATION OF



NANOMEDICINE FOR DIAGNOSTICS AND THERAPY IN ONCOLOGY

PLAN OF ROOMS AND TABLES FOR MEETINGS (PARTNERING)



WITH THE COLLABORATION OF